Renalytix Share Discussion Threads

[mr roper] 26/8/2021 07:31

Some good numbers there.
Saving of $1.1bn over 5 years per 100,000 patients.

Clinically obese adults in the US project to hit 30% of adult population this decade.
Call that 60m plus and the potential savings are mind blowing.

[wan] 24/8/2021 15:22

Just a quick note - I note that both Renalytix labs, New York and Salt Lake City have both attained a CLIA Certificate of Compliance, which is issued to a laboratory after an inspection by a CLIA state survey agency that finds the laboratory to be in compliance with all applicable CLIA requirements.

As opposed to CLIA (Clinical Laboratory Improvement Amendments) Certificate of Registration, which I believe Salt Lake City had and was temporary and permits the laboratory to conduct nonwaived (moderate and/or high complexity) tests until the laboratory is inspected and found to be in compliance with CLIA regulations.

[wan] 20/8/2021 07:32

Two stories worthy of investor attention -

Who will prevail as the medical and technology worlds collide?
BY JOE CORRIGAN 19 AUGUST 2021

Joe Corrigan, head of intelligent healthcare, Cambridge Consultants, part of Capgemini Invent, examines the ‘collision’ of the medical and technology worlds.

With the slow inevitability of tectonic plates, the medical and technology worlds are colliding. From a distance, it seems that nothing is happening. But the ground is rising. New ways of working are being enabled by artificial intelligence (AI), data and edge computing. Doctors, patients and researchers are – like all of us – immersed in consumer-focussed digital services, which adds to the relentless pressure. This means that when a new user-centric medical service is launched, there can be sudden, seismic shifts in behaviour. Being able to foresee or cause these quakes will determine who ends up at the top of the mountain.

Nevertheless, as we go forward it will no longer be enough to simply ship the drug – companies will have to consider how it fits into the patient’s lifestyle and shape a service accordingly. This means coming to terms with the interpretation of real-time data. The ability to develop AI models that continually ingest data from devices to learn from and rapidly iterate product is familiar to the likes of Amazon but unfamiliar to pharma. For now.

The emphasis will pivot to demonstrating outcomes that are not set in stone solely by clinical trials but are rethought and readdressed by consumer behaviour. Outcomes that are influenced by whether the patient takes the drug or experiences real-world benefits. The key opinion leaders – the doctors and other healthcare professionals – will be the kingmakers here, along with patients. They may very well prefer the service to a competing drug because it considers behaviours that improve outcomes.

Medical devices are entirely different in that for each condition there are unique biomarkers that can be used to derive user actionable insights. And as I mentioned above, the support for the biomarkers comes from the KOLs in those markets. And when those user insights can be demonstrated to provide value to the end-user through outcomes, it becomes a truly differentiating opportunity for a manufacturer. Each patient group and subset of that group becomes a market with an independent platform value. So, we are likely to see commoditisation of certain services such as sharing data and secure storage, but clear differentiation and value that derives from niche applications that sit on those platforms.

In its paper – ‘Six winning roles for MedTech to thrive in the future of health’ – Deloitte identifies its most influential trends: data-sharing, interoperable data, access, empowered consumer, behaviour change and scientific breakthrough. Most of these are fuel to the fire of the tipping point of transformative data abilities I’ve described. Coming advances in AI, technology and interoperability will enable the next stage of evolution… the big switch to a data structure that allows for the network effect, the ‘Google moment’, and market domination. It’s time to listen to the tremors and act on them.

Full article -

NICE launches public consultation on tech evaluation programmes
19 AUGUST 2021

NICE has today launched a public consultation on proposed changes to the way it develops recommendations across its health technology evaluation programmes.

From today until 13 October 2021, NICE is seeking feedback on proposed changes to its health technology assessment methods, and processes. The consultation is the culmination of the most wide-ranging and comprehensive review NICE has ever carried out, which has involved health system partners as well as industry, healthcare professionals, academia, and patients.

The proposed changes signal how NICE is evolving alongside technological advances in medicines and data synthesis to continue to deliver excellence for patients, the NHS and the life sciences industry. These changes aim to provide greater predictability for industry, greater transparency for stakeholders and enable swift decision making for our committees.

The over-arching ambition of the proposals are to provide:

Earlier access to valuable new innovative treatments.
More equitable access to treatments for those with severe diseases.
Greater clarity and predictability of health technology assessment outcomes.
Enhanced flexibility in the use of a comprehensive evidence base, including use of real-world data.
Support for the life sciences vision of making the UK a more attractive place for life sciences companies to succeed and grow.

NICE is also seeking feedback on its eligibility criteria for devices, diagnostics and digital technologies and the aim and routing criteria for topics for evaluation through NICE’s Highly Specialised Technologies programme.

Meindert Boysen, deputy chief executive and director of the Centre for Health Technology Evaluation at NICE, said: “Operating at the interface between the world in which new treatments are developed and the NHS in which they are used, NICE occupies a unique position in managing the lifecycle of innovative health technologies.

“Our methods and processes are central to an internationally attractive life sciences offer in which we work collaboratively with our partners across the regulatory and life-sciences landscape on speeding up access to promising innovative new health technologies, including through the Cancer Drugs Fund, Innovative Licensing and Access Pathway, the forthcoming Innovative Medicines Fund and activities of the Accelerated Access Collaborative such as the MedTech Funding Mandate.

“Ensuring that our methods and processes are clear, transparent and predictable, these proposals further emphasise our commitment to making the journey for promising new health technologies even faster, and patient access fairer.”

NICE has confirmed that, following the completion of this review, it will move to a dynamic, modular approach to updating its methods and processes combined with improved horizon scanning for emerging methodological developments and challenges. The aim is to proactively adapt to new innovations and secure seamless evaluation and rapid access. Future modular updates for the methods will include health inequalities, digital technologies, genomics and antimicrobials alongside processes for managing technologies with multiple indications and rapid entry to managed access.

Full article -

[toffeeman] 19/8/2021 13:40

>> Wan red

tvm

[rampmeister] 19/8/2021 10:14

At least we have offloaded some weak holders. Onwards and upwards.

RM

[red171] 19/8/2021 10:08

Brum1875 on LSE posted this yesterday

In the absence of news (let’s wait and see), the -20% share price drop seems to have originated from the US. The stock got hit at the open by a -80k sale which compares to a daily average volume of 40k. It could be a forced seller or someone placing big bets in the options market. Anyway, this high volatility is typical of August time when institutional investors are on holiday and trading is mainly driven by smaller/private investors. Hence, most companies tend to avoid releasing market sensitive news at that time and prefer to wait until September to communicate. Obviously, Management have a duty to release any unexpected news, good or bad, as soon as it is known. Fingers crossed this is not the case today.


Perhaps that is linked to the Tarbin Shahpuri tweet above
Parian Global Management LP Investments has a chunk of smaller biotech. They have been selling down RNLX.

Parian reported holding 513,816 at 30 June after having sold 319,673 that quarter.
hxxps://whalewisdom.com/filer/parian-global-management-lp#tabholdings_tab_link

[wan] 19/8/2021 09:40

Maybe some misinterpreted the gene discovery news in some way as affecting the effectiveness and need for KidneyIntelx? However, in my view it highlights the need for powerful technology such as KidneyIntelx to mine its way through the existing and 'emerging' wide range of data to the most important, influential and impactful elements and align that with the necessary and appropriate clinical action, including drug development and precision medicine (cue the partnership with AstraZeneca).

[toffeeman] 19/8/2021 09:07

>> Wan

So why the drop yesterday?

[wan] 19/8/2021 07:55

Recall that KidneyIntelx has already been deployed and launched commercially within Mount Sinai, and to perhaps underscore my point above regarding genetics and the use of diverse electronic medical record systems to identify genetic risk etc -

Targeting At-Risk Patients Through Precision Medicine
More than 47,000 DNA and blood serum specimens from Mount Sinai’s diverse population of patients are housed at the BioMe Biobank, which is part of the Charles Bronfman Institute for Personalized Medicine. The Mount Sinai team is using these specimens in conjunction with AI to determine which patients may be at risk for kidney failure and the need for dialysis. BioMe is also linked to Mount Sinai’s electronic health records, and AI enables scientists to conduct genetic, epidemiologic, molecular, and genomic studies rapidly and efficiently with large collections of research specimens linked with medical information.

[wan] 18/8/2021 18:30

Predicting the future of healthcare: 10 takeaways from HIMSS21
Along with 'guarded optimism' on the current state of the pandemic, some 19,000 onsite attendees in Las Vegas mulled over what's next for AI, telehealth, cybersecurity, femtech and more.

Published Aug. 17, 2021

The crowds at HIMSS this year may have been smaller due to COVID-19 concerns, but the conversations at the annual health IT conference were just as weighty as prior years.

Artificial intelligence, machine learning gains steam
Unsurprisingly, artificial intelligence and machine learning were front and center at the conference, with executives at many leading systems talking about how they've been ramping up investments in algorithms during COVID-19.
Full story -

[homebrewruss] 18/8/2021 17:19

US price bouncing back pretty well now. Hopefully the UK will continue bouncing tomorrow.
Bought another 10% today, annoyingly I also bought some a couple of days ago before the sale.

[wan] 18/8/2021 17:11

I read the original release for the article posted further above, which was actually reported elsewhere last week, so it's not exactly new news -


But regardless, I saw the findings as potentially good news for kidney disease sector and sufferers, and potentially good news if any of those findings can be augmented further by AI such as Kidneyintelx. And as I said earlier, kidneyintelx already utilises a diverse range of data inputs, including genetics.

[homebrewruss] 18/8/2021 17:04

Some speculation that a fund has been selling down their stake

[9degrees] 18/8/2021 16:50

what is happening to the share on US market?

[andrewbaker] 18/8/2021 16:37

The price drop is so much a buying opportunity. Just 'cos someone inside needs or wants to raise cash, doesn't affect the company's potential, which is, IMHO, so very good.

[elsa7878] 18/8/2021 16:25

Someone has posted the article above so not sure why some are speculating as to why the shareprice is down unless you are finding it hard to put 2 and 2 together. If kidney disease is largely a function of genetics and if those genetics are understood then AI is at a minimum less useful as a tool...I guess.
Whether the article justifies this drop. I don't know and I'm not a shareholder.

[donald pond] 18/8/2021 16:12

Managed to open a spread bet around 2100, which was lucky. If this is just a fake move it's a great opportunity, if it's someone selling on inside info, eek

[rollercoaster4] 18/8/2021 16:10

us tech sell off in small caps, dragging renx down with it

[74tom] 18/8/2021 16:05

Far more likely that a AI quant company that has inputted the current market cap, revenue, director selling & the current US Covid resurgence and come out with a decision to short sell. Either way, buying at a near 25% discount to yesterday's opening price is a decent insurance policy.

Ps. NASDAQ is very much the dog, and any fundraising would be done over there... however with around $70m on the balance sheet as of last Q, there is almost certainly no immediate need for cash.

[red171] 18/8/2021 15:48

bought too, y, it is a concern! what's going on? any ideas?

[toffeeman] 18/8/2021 15:46

Two possible reasons

1. Something nasty has occurred

2. Discounted fundraise

The hell of AIM!

[seamusm99] 18/8/2021 15:43

just bought easily on HL - bit of a gamble not knowing why the drop but I've faith in the company and thought I'd increase my holding

[toffeeman] 18/8/2021 15:40

A drop of 20% has to be a concern, can't just sit there and ignore.

[red171] 18/8/2021 15:31

don't know, can't find anything

but can't buy either on HL